WallStSmart

Ke Holdings Inc (BEKE)vsEUDA Health Holdings Limited (EUDA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Ke Holdings Inc generates 1300029% more annual revenue ($88.67B vs $6.82M). BEKE leads profitability with a 5.3% profit margin vs -40.7%. BEKE earns a higher WallStSmart Score of 59/100 (C).

BEKE

Buy

59

out of 100

Grade: C

Growth: 6.7Profit: 4.5Value: 7.3Quality: 7.5
Piotroski: 4/9Altman Z: 2.02

EUDA

Avoid

24

out of 100

Grade: F

Growth: 8.0Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -47.30
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BEKEUndervalued (+10.5%)

Margin of Safety

+10.5%

Fair Value

$21.06

Current Price

$16.93

$4.13 discount

UndervaluedFair: $21.06Overvalued

Intrinsic value data unavailable for EUDA.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BEKE4 strengths · Avg: 9.3/10
PEG RatioValuation
0.4310/10

Growing faster than its price suggests

EPS GrowthGrowth
111.5%10/10

Earnings expanding 111.5% YoY

Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

EUDA2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
78.9%10/10

Revenue surging 78.9% year-over-year

Debt/EquityHealth
-0.5610/10

Conservative balance sheet, low leverage

Areas to Watch

BEKE4 concerns · Avg: 3.0/10
P/E RatioValuation
28.4x4/10

Moderate valuation

Return on EquityProfitability
7.2%3/10

ROE of 7.2% — below average capital efficiency

Profit MarginProfitability
5.3%3/10

5.3% margin — thin

Revenue GrowthGrowth
-5.7%2/10

Revenue declined 5.7%

EUDA4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$40.81M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-2.50M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BEKE

The strongest argument for BEKE centers on PEG Ratio, EPS Growth, Debt/Equity. PEG of 0.43 suggests the stock is reasonably priced for its growth.

Bull Case : EUDA

The strongest argument for EUDA centers on Revenue Growth, Debt/Equity. Revenue growth of 78.9% demonstrates continued momentum.

Bear Case : BEKE

The primary concerns for BEKE are P/E Ratio, Return on Equity, Profit Margin.

Bear Case : EUDA

The primary concerns for EUDA are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

BEKE profiles as a value stock while EUDA is a hypergrowth play — different risk/reward profiles.

EUDA carries more volatility with a beta of 0.64 — expect wider price swings.

EUDA is growing revenue faster at 78.9% — sustainability is the question.

Monitor REAL ESTATE SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

BEKE scores higher overall (59/100 vs 24/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Ke Holdings Inc

REAL ESTATE · REAL ESTATE SERVICES · China

KE Holdings Inc. is involved in the operation of an integrated online and offline platform for housing transactions and services in the People's Republic of China. The company is headquartered in Beijing, China.

EUDA Health Holdings Limited

REAL ESTATE · REAL ESTATE SERVICES · USA

EUDA Health Holdings Limited is a forward-looking biopharmaceutical company focused on innovating treatments for rare diseases and addressing unmet medical needs. Leveraging advanced technologies, the firm is developing a robust clinical pipeline with a particular emphasis on supportive care and immune modulation. EUDA's strong commitment to research and development positions it favorably in the healthcare landscape, aiming to enhance patient outcomes and expand access to crucial therapies.

Visit Website →

Want to dig deeper into these stocks?